With the rising prevalence of chronic diseases and growth of biologics, MC Pro recommends holding Gland Pharma. Post the recent correction and downward adjustments in estimates, Gland Pharma is trading at 17x EV/EBITDA for FY24e. Here’s why it makes for a good investment bet.
first published: Jun 23, 2022 07:19 pm
A collection of the most-viewed Moneycontrol videos.
Live: Sensex, Nifty retreat after mounting on new lifetime highs | Closing Bell
Live: Will bulls take Nifty to fresh lifetime highs today? | Opening Bell
Live: Nifty sees best single day rally since June 2025, nears record high | Closing Bell
Live: Can Nifty claim new lifetime highs in December series? | Opening Bell
Is it a good time to enter Bajaj Finance post Q3 business update? | Opening Bell
Attractive valuation, strong earnings potential: Buy this stock for the long term | Ideas for Profit
Vesuvius India made fresh lifetime high. Right time to buy the stock or wait for a drop?
Indian Hotel Industry Sees Strong Demand; Buy This Stock For Sector Upcycle | Ideas For Profit
Can strong auto demand drive this company’s stock further? | Ideas For Profit
